^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Zydelig (idelalisib) (PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
CLL/SLL with del(17p)/TP53 mutation: Relapsed/refractory therapy...Other recommended regimens…Idelalisib
